Mylan Pharmaceuticals Inc: Drug Recall
Recall #D-0774-2022 · 04/07/2022
Class II: Risk
Recall Details
- Recall Number
- D-0774-2022
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- Mylan Pharmaceuticals Inc
- Status
- Terminated
- Date Initiated
- 04/07/2022
- Location
- Morgantown, WV, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 33,893 vials
Reason for Recall
Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.
Product Description
Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60
Distribution Pattern
Nationwide in the USA
Other Recalls by Mylan Pharmaceuticals Inc
- Class II: Risk 02/25/2025
- Class I: Dangerous 07/05/2022
- Class I: Dangerous 04/12/2022
- Class II: Risk 04/01/2022
- Class II: Risk 01/21/2022
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.